<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03043313</url>
  </required_header>
  <id_info>
    <org_study_id>SGNTUC-017</org_study_id>
    <secondary_id>NCI-2017-01107</secondary_id>
    <secondary_id>ACCRU-GI-1617</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03043313</nct_id>
  </id_info>
  <brief_title>Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer</brief_title>
  <official_title>MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academic and Community Cancer Research United</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well the drug tucatinib works when given with trastuzumab and when&#xD;
      given by itself. The participants in this trial have HER2-positive (HER2+) metastatic&#xD;
      colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the&#xD;
      body.&#xD;
&#xD;
      In the first part of this study, participants enrolled into Cohort A and received both&#xD;
      tucatinib and trastuzumab. In the second part of this study, participants are randomly&#xD;
      assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and&#xD;
      trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do&#xD;
      not respond to therapy may have an option to receive tucatinib plus trastuzumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 23, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed objective response rate (cORR) per RECIST 1.1 per blinded independent central review (BICR) in pooled Cohorts A+B</measure>
    <time_frame>Up to 8 months</time_frame>
    <description>cORR is defined as confirmed complete response (CR) or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR at 12 weeks of treatment per RECIST 1.1 according to BICR assessment</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>ORR by Week 12 is defined as the proportion of participants with CR or PR by 12 weeks of treatment, and before time of crossover (Cohort C), whichever comes earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per RECIST 1.1 according to BICR assessment</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>DOR is defined as the time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease or to death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) per RECIST 1.1 according to BICR assessment for pooled Cohorts A+B</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>PFS is defined as the time from start of study treatment (Cohort A) or randomization (Cohort B) to first documentation of tumor progression or to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in pooled Cohorts A+B</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>OS is defined as the time from start of study treatment (Cohort A) or randomization (Cohort B) to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Through 30 days following last dose; up to approximately 9 months overall per subject</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose modifications</measure>
    <time_frame>Through 30 days following last dose; up to approximately 9 months overall per subject</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 30 days following last dose; up to approximately 9 months overall per subject</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Metastatic Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort A: Tucatinib + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Tucatinib + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Tucatinib Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized cohort. Participants take tucatinib twice per orally every day. Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Given intravenously (into the vein; IV)</description>
    <arm_group_label>Cohort A: Tucatinib + Trastuzumab</arm_group_label>
    <arm_group_label>Cohort B: Tucatinib + Trastuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Cohort A: Tucatinib + Trastuzumab</arm_group_label>
    <arm_group_label>Cohort B: Tucatinib + Trastuzumab</arm_group_label>
    <arm_group_label>Cohort C: Tucatinib Monotherapy</arm_group_label>
    <other_name>ARRY-380</other_name>
    <other_name>ONT-380</other_name>
    <other_name>TUKYSA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histologically and/or cytologically documented adenocarcinoma of the colon or rectum&#xD;
             that is metastatic and/or unresectable&#xD;
&#xD;
          -  Unless contraindicated, participants must have received and failed regimens containing&#xD;
             the following agents: fluoropyrimidine (e.g., 5-fluorouracil or capecitabine),&#xD;
             oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody (bevacizumab, ramucirumab,&#xD;
             or ziv-aflibercept), and an anti-PD-(L)1 therapy (nivolumab or pembrolizumab) if tumor&#xD;
             has deficient mismatch repair proteins or is MSI-High.&#xD;
&#xD;
          -  Have progression of unresectable or metastatic CRC after the last systemic therapy, or&#xD;
             be intolerant of last systemic therapy&#xD;
&#xD;
          -  Have RAS wild-type in primary or metastatic tumor tissue, based on expanded RAS&#xD;
             testing&#xD;
&#xD;
          -  Willing and able to provide the most recently available tissue blocks obtained prior&#xD;
             to treatment initiation. If archival tissue is not available, then a newly-obtained&#xD;
             baseline biopsy of an accessible tumor&#xD;
&#xD;
          -  Have confirmed HER2-positive mCRC, as defined by having tumor tissue tested at a&#xD;
             Clinical Laboratory Improvement Act (CLIA)-certified or International Organization for&#xD;
             Standardization (ISO)-accredited laboratory, meeting at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               -  HER2+ overexpression (3+ immunohistochemistry [IHC]) by an FDA-approved or&#xD;
                  Conformité Européene (CE)-marked HER2 ICH test&#xD;
&#xD;
               -  HER2 2+ IHC is eligible if the tumor is amplified by an FDA-approved or CE-marked&#xD;
                  HER2 in situ hybridization assay (FISH or chromogenic in situ hybridization&#xD;
                  [CISH]))&#xD;
&#xD;
               -  HER2 (ERBB2) amplification by CLIA-certified or ISO-accredited next generation&#xD;
                  sequencing (NGS) sequencing assay&#xD;
&#xD;
          -  Have radiographically measurable disease assessable by RECIST 1.1, with at least one&#xD;
             site of disease that is measurable and that has not been previously irradiated; or, if&#xD;
             the participant has had previous radiation to the target lesion(s), there must be&#xD;
             evidence of progression since the radiation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2&#xD;
&#xD;
          -  Life expectancy greater than 3 months&#xD;
&#xD;
          -  Have adequate hematological, hepatic, renal, coagulation, and cardiac function&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Previous treatment with anti-HER2 targeting therapy&#xD;
&#xD;
          -  Previous treatment with any systemic anticancer therapy, non-central nervous system&#xD;
             radiation, or experimental agent within 3 weeks of first dose of study treatment&#xD;
&#xD;
          -  Toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with&#xD;
             the following exceptions:&#xD;
&#xD;
               -  Alopecia and neuropathy, which must have resolved to ≤ Grade 2&#xD;
&#xD;
               -  Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the&#xD;
                  time of occurrence, and must have resolved completely&#xD;
&#xD;
               -  Anemia, which must have resolved to ≤ Grade 2&#xD;
&#xD;
               -  Decreased ANC, which must have resolved to ≤ Grade 2&#xD;
&#xD;
          -  Have clinically significant cardiopulmonary disease&#xD;
&#xD;
          -  Have known myocardial infarction, unstable angina, cardiac or other vascular stenting,&#xD;
             angioplasty, or cardiac surgery within 6 months prior to first dose of study treatment&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury ≤28 days prior&#xD;
             to enrollment (≤56 days for hepatectomy, open thoracotomy, or major neurosurgery) or&#xD;
             anticipation of need for major surgical procedure during the study&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Known to be positive for hepatitis B by surface antigen expression&#xD;
&#xD;
          -  Known to have active hepatitis C infection&#xD;
&#xD;
               -  Exception for participants with a documented sustained virologic response of 12&#xD;
                  weeks&#xD;
&#xD;
          -  Known to be positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Subjects who are pregnant, breastfeeding, or planning a pregnancy&#xD;
&#xD;
          -  Inability to swallow pills or any significant gastrointestinal disease which would&#xD;
             preclude the adequate oral absorption of medications&#xD;
&#xD;
          -  Have used strong CYP2C8 inhibitor within 5 half-lives of the inhibitor, or have used a&#xD;
             strong CYP2C8 or CYP3A4 inducer within 5 days prior to first dose of study treatment&#xD;
&#xD;
          -  History of another malignancy within 3 years before the first dose of study drug, or&#xD;
             any evidence of residual disease from a previously diagnosed malignancy.&#xD;
&#xD;
               -  Exceptions are malignancies with a negligible risk of metastasis or death&#xD;
&#xD;
          -  Subjects with known active CNS metastasis&#xD;
&#xD;
               -  Irradiated or resected lesions are permitted, provided the lesions are fully&#xD;
                  treated and inactive, subject is asymptomatic, and no steroids have been&#xD;
                  administered for at least 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H Strickler</last_name>
    <role>Study Chair</role>
    <affiliation>Academic and Community Cancer Research United</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Stecher, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Medical Center / University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Heritage Medical Group</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Cancer Center / Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South Region</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North Region</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University / University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology-Nashville/Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Beaumont</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702-1449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center Everett</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <state>Other</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Other</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Other</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitalier Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <state>Other</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <state>Other</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Franco-Britannique - Fondation Cognacq-Jay</name>
      <address>
        <city>Levallois-Perret</city>
        <state>Other</state>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes</name>
      <address>
        <city>Lyon</city>
        <state>Other</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <state>Other</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <state>Other</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niguarda Ca' Granda Hospital</name>
      <address>
        <city>Milan</city>
        <state>Other</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana - Ospedale S. Chiara</name>
      <address>
        <city>Pisa</city>
        <state>Other</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals - Institut Catala d'Oncologia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Other</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Other</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>ERBB2</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Tucatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

